Entrectinib is a Game-changer for the Treatment of NTRK/ROS1/ALK Fusion-positive Solid Tumors

Microscope in the Laboratory, modern close-up shot

Entrectinib (RXDX-101), an investigational anticancer agent being developed by Ignyta, is a game-changer for NTRK/ROS1/ALK fusion-positive solid tumors.

The San Diego, California-based biotechnology company is attracting attention for its orally available central nervous system (CNS) active tyrosine kinase inhibitor, entrectinib, which is in a strong position to progress to market, according to researchers at GlobalData, a leading data and analytics company.

During the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), which took place June 2nd to the 5th in Chicago, Illinois, the team behind The Onco’Zine Brief sat down with Jonathan E. Lim, MD. During our interview Lim taked about some of the exciting clinical data presented at ASCO, including the development of novel treatments that target gene fusions that drive tumor growth. These new approaches are focused on molecular targets rather than tumor histology, and they are changing the way we look at cancer treatment for a range of patients with unmet medical needs. At Ignyta, Lim focuses on the mission of developing precision medicines that can eventually eradicate residual disease in certain, well-defined, cancer populations. To listen, follow the link.

PRIME Designation
The drug has already been granted an FDA breakthrough therapy designation in May 2017 and an FDA orphan drug designation in July 2017.

On October 17, the EMA awarded entrectinib a Priority Medicines (PRIME) designation, following the company’s release of its updated clinical trial results for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

?The PRIME designation allows Ignyta to have enhanced support from the regulatory body, including optimizing the development pathway and engaging in early discussions with both the EMA and health technology assessment bodies in Europe.

This initiative will place the multi-targeted kinase inhibitor on a faster path to approval and ease subsequent access barriers,? noted Ashwin Oberoi, Healthcare Analyst at GlobalData.

STARTRK-2 trial
The ongoing, global, multicenter, open-label, Phase II STARTRK-2 trial is evaluating entrectinib in a basket trial design, in which patients with a variety of tumor types are eligible for the therapy.

As part of this basket trial design, entrectinib is currently being analyzed in NSCLC, salivary gland cancer, pancreatic cancer, metastatic colorectal cancer (mCRC), neuroblastoma, and papillary thyroid cancer.

Video: A Clinical Trial for Many Kinds of Advanced Cancers | STARTRK Trials

“The multi-kinase inhibitor entrectinib has proven to have a drastic effect in the NTRK, ROS1, and ALK fusion-positive solid tumor patient cohorts. With Ignyta?s positive Phase II data in an NSCLC population, enhanced regulatory body support from both the EMA and FDA, and significant capital raised, the company should be in a robust position to drive its prized asset through to the finish line,” Oberi continued:

?However, Ignyta?s upcoming planned Phase III trial and data readouts will be critical for determining entrectinib?s future in the precision medicine space for patients with advanced and metastatic solid tumors,? he concluded.


Last Editorial Review: November 17, 2017

Featured Image: Microscope in the Laboratory, modern close-up sho Courtesy: ? Fotolia. Used with permission.

Copyright ? 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.